Nortech Systems Inc. (NSYS) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This filing covers the quarterly period ended June 30, 2025. Nortech Systems Inc. is a global EMS contract manufacturer serving the Medical Device, Medical Imaging, Aerospace and Defense, and Industrial markets. The company operates facilities in the United States (Minnesota), Mexico, and China. During the period, the company completed the closure of its Blue Earth, MN facility (sold in July 2025) and continued restructuring activities to align staffing with forecasted sales.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Net Sales | $30.7M | $33.9M | $57.6M | $68.1M |
| Gross Profit | $4.8M | $4.6M | $7.9M | $10.1M |
| Gross Margin | 15.8% | 13.6% | 13.7% | 14.8% |
| Operating Income (Loss) | $0.7M | $0.3M | $(0.9M) | $1.5M |
| Net Income (Loss) | $0.3M | $0.2M | $(1.0M) | $0.9M |
| Cash from Operations | N/A | N/A | $(2.8M) | $(1.5M) |
| Ending Cash Balance | $0.7M | N/A | $0.7M | N/A |
| Debt (Line of Credit) | $11.6M | N/A | $11.6M | $8.7M |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 9.5% in Q2 and 15.5% YTD compared to 2024. The decline was driven by delays in Aerospace and Defense customer approvals following the transfer of production from the closed Blue Earth facility to Bemidji, as well as inventory re-balancing in the Medical Device sector.
- Profitability: While Q2 operating income improved to $0.7M (up from $0.3M in Q2 2024) due to better gross margins and lower incentive compensation, the YTD period resulted in an operating loss of $0.9M compared to income of $1.5M in the prior year.
- Restructuring: The company incurred $0.3M in restructuring charges YTD 2025 (primarily Q1 severance and facility costs), compared to $0.1M in the prior year. No restructuring charges were recorded in Q2 2025.
- Debt Utilization: Borrowings under the revolving line of credit increased to $11.6M from $8.7M at year-end 2024 to support working capital needs.
Guidance, Outlook, and Risks
- Debt Covenants & Amendments: The company has faced covenant non-compliance regarding leverage and fixed charge ratios. It secured a "First Amendment" (March 2025) and "Second Amendment" (May 2025) to its credit facility, deferring compliance testing to Q4 2025. A "Third Amendment" (July 2025) extended the facility maturity to August 2026. These amendments increased borrowing rates and imposed minimum EBITDA and liquidity requirements.
- Operational Outlook: Management expects the production transfer issues in Aerospace and Defense to resolve over the next two quarters. Cost-cutting initiatives and inventory reduction plans are intended to drive reduced borrowings in the remainder of 2025.
- Backlog: Total order backlog increased 6.9% to $78.4M, driven by large medical device orders, though the 90-day shipment backlog decreased slightly to $26.6M.
- Risks: Key risks include potential impairment of long-lived assets if fair value declines, failure to meet amended debt covenants, and continued supply chain or customer approval delays.
Investor Verification Checklist
- Covenant Compliance: Verify the company's ability to meet the specific EBITDA and liquidity thresholds mandated by the Second Amendment to the credit facility by Q4 2025.
- Asset Impairment: Monitor the valuation of long-lived assets, particularly given the stock price trading below net equity value and the recent sale of the Blue Earth facility.
- Customer Concentration: Note that "Customer A" represents 31% of Q2 net sales and 22% of accounts receivable; assess the stability of this relationship.
- Cash Flow Sustainability: Review the trend of negative operating cash flow ($2.8M used YTD) against the $11.6M debt balance to ensure liquidity remains sufficient for the next 12 months.
- Restructuring Completion: Confirm that no significant additional restructuring costs remain, as the company stated it does not expect significant additional expenses related to the current plan.